Cerebral Protection Mitigates TAVI Cognitive Decline 09/01/25

Welcome to Cardiology Today – Recorded September 01, 2025. This episode summarizes 5 key cardiology studies on topics like biomarker and mitral regurgitation. Key takeaway: Cerebral Protection Mitigates TAVI Cognitive Decline. Article Links: Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. (Circulation) Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. (Circulation) Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. (Circulation) Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. (Circulation) Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. (Circulation) Tap ‘more’ for full notes and links. Full episode page: https://podcast.explainheart.com/podcast/cerebral-protection-mitigates-tavi-cognitive-decline-09-01-25/ Full Episode Summary This episode covers recent research from top journals like NEJM and JACC. Tap ‘more’ for details. Featured Articles Article 1: Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40886109 Summary: The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes. Article 2: Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884786 Summary: This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure. Article 3: Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884774 Summary: This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions. Article 4: Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884771 Summary: This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting. Article 5: Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. Journal: Circulation PubMed Link: https://pubmed.ncbi.nlm.nih.gov/40884768 Summary: This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis. <h3> Transcript</h3> <div style=”background-color: #f8f9fa; padding: 20px; border-radius: 5px; line-height: 1.6;”> <p><em>Today’s date is September 01, 2025. Welcome to Cardiology Today. Here are the latest research findings.</em></p><p>Article number one. Clinical Presentation and Outcomes After Surgery for Mitral Regurgitation: Real-World Insights From the MITRACURE International Registry. The MITRACURE registry, a large international retrospective study, examined patients undergoing mitral valve surgery for mitral regurgitation. The registry provides insights into contemporary management strategies, adherence to guidelines, and potential selection biases in mitral valve surgery. This data can be used to inform quality improvement initiatives and optimize patient outcomes.</p><p>Article number two. Impact of Cerebral Embolic Protection On Cognitive Function Following Transcatheter Aortic Valve Implantation: Data From the BHF PROTECT-TAVI Randomized Trial. This secondary analysis of the BHF PROTECT-TAVI trial investigated the impact of cerebral embolic protection devices on cognitive function after transcatheter aortic valve implantation. The trial demonstrated that cerebral embolic protection reduced the incidence of neurocognitive decline in patients undergoing transcatheter aortic valve implantation for aortic stenosis. The findings suggest cerebral embolic protection may mitigate cognitive impairment risk during the procedure.</p><p>Article number three. Biomarker-based ABC-AF Risk Scores for Personalized Treatment to Reduce Stroke or Death in Atrial Fibrillation – a Registry-based Multicenter Randomized Controlled Study. This multicenter, registry-based randomized controlled study evaluated whether using a biomarker-based ABC Atrial Fibrillation (ABC-AF) risk score to guide treatment improves outcomes in individuals with atrial fibrillation. The study aims to determine if a personalized, multidimensional treatment approach based on the ABC-AF risk score reduces the risk of stroke or death. The trial is ongoing, evaluating clinical utility of risk scores to guide treatment decisions.</p><p>Article number four. Ivabradine in Patients Undergoing Noncardiac Surgery: a Randomized Controlled Trial. This randomized controlled trial examined the use of ivabradine, a selective heart rate-lowering agent, in patients undergoing noncardiac surgery. The study sought to determine if ivabradine could prevent myocardial injury after noncardiac surgery without causing hemodynamic instability, a known risk with beta-blockers. The results will show whether ivabradine is a safe and effective alternative to beta-blockers for heart rate control in this setting.</p><p>Article number five. Three-Year-Follow-Up of the NOTION-2 Trial: TAVR Versus SAVR to Treat Younger Low-Risk Patients with Tricuspid or Bicuspid Aortic Stenosis. This three-year follow-up of the NOTION-2 trial compared transcatheter aortic valve replacement to surgical aortic valve replacement in younger, low-risk patients with severe tricuspid or bicuspid aortic stenosis. The study evaluated mid-term outcomes in patients aged 60 to 75 years undergoing either transcatheter aortic valve replacement or surgery. The trial will help inform treatment decisions for younger patients with aortic stenosis.</p><p><em>Thank you for listening. Tap ‘more’ for full notes and links.</em></p> </div> Keywords biomarker, mitral regurgitation, ivabradine, mitral valve surgery, noncardiac surgery, valve replacement, stroke, transcatheter aortic valve implantation, MITRACURE registry, bicuspid aortic valve, surgical aortic valve replacement, transcatheter aortic valve replacement, atrial fibrillation, low-risk patients, heart rate control, myocardial injury, randomized controlled trial, aortic stenosis, cerebral embolic protection, valve repair, cognitive function, beta-blockers, stroke prevention, ABC-AF risk score. About Concise summaries of cardiovascular research for professionals. Subscribe • Share • FollowThe post Cerebral Protection Mitigates TAVI Cognitive Decline 09/01/25 first appeared on Cardiology Today.